XML 23 R12.htm IDEA: XBRL DOCUMENT v3.25.1
ADDITIONAL BALANCE SHEET DETAIL
 3 Months Ended
Mar. 31, 2025
Payables and Accruals [Abstract]  
ADDITIONAL BALANCE SHEET DETAIL ADDITIONAL BALANCE SHEET DETAIL
Prepaid expenses and other current assets are as follows (in thousands):
DescriptionMarch 31, 2025
December 31, 2024
Prepaid manufacturing$1,221 $4,029 
Other7,917 7,321 
Total prepaid expenses and other current assets$9,138 $11,350 
Prepaid manufacturing expenses include advance payments to contract manufacturing organizations, or CMOs, for APIs or drug substance. Such amounts are reclassified to work-in-process inventory upon the quality release of the batches and transfer of title to the Company from the CMO.
Other long-term assets are as follows (in thousands):
DescriptionMarch 31, 2025
December 31, 2024
Long-term inventories$35,966 $34,953 
Restricted cash1,685 1,680 
Other690 744 
Total other long-term assets$38,341 $37,377 
See Note 4, Inventories, for further information on long-term inventories.
Accrued expenses and other current liabilities consists of the following (in thousands): 
Description
March 31, 2025December 31, 2024
Product revenue allowances$27,451 $15,727 
Product return reserves, current portion5,186 5,295 
Clinical trial costs773 1,885 
Compensation and related benefits5,673 9,194 
Operating lease liabilities, current portion5,514 5,400 
Royalties due to Panion & BF Biotech, Inc.3,267 3,543 
Professional fees1,035 1,452 
Accrued manufacturing costs1,580 1,468 
Restructuring costs251 489 
BioVectra, Inc. termination fees4,894 7,204 
Liability related to sale of future royalties, current portion2,048 2,039 
Settlement royalties liability, current portion10,577 5,924 
Other3,088 3,840 
Total accrued expenses and other current liabilities$71,337 $63,460